✦ LIBER ✦

Imatinib for priority review by US FDA for GIST recurrence.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cetuximab sBLA accepted for priority rev

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

The US FDA has granted priority review f

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

US FDA grants priority review status for

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Treprostinil NDA accepted for review by

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

FDA Review Practices and Priorities for

✍ KEN KOBAYASHI; ROBERT J. DELAP 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB